-
Je něco špatně v tomto záznamu ?
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
L. Albiges, T. Powles, M. Staehler, K. Bensalah, RH. Giles, M. Hora, MA. Kuczyk, TB. Lam, B. Ljungberg, L. Marconi, AS. Merseburger, A. Volpe, Y. Abu-Ghanem, S. Dabestani, S. Fernández-Pello, F. Hofmann, T. Kuusk, R. Tahbaz, A. Bex,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi
- MeSH
- axitinib aplikace a dávkování MeSH
- bevacizumab aplikace a dávkování MeSH
- humanizované monoklonální protilátky aplikace a dávkování MeSH
- ipilimumab aplikace a dávkování MeSH
- karcinom z renálních buněk farmakoterapie sekundární MeSH
- lidé MeSH
- nádory ledvin farmakoterapie patologie MeSH
- nivolumab aplikace a dávkování MeSH
- protokoly antitumorózní kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- sunitinib terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
Academic Urology Unit University of Aberdeen Aberdeen UK
Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France
Department of Clinical Sciences Lund Lund University Skåne University Hospital Malmö Sweden
Department of Surgical and Perioperative Sciences Urology and Andrology Umeå University Umeå Sweden
Department of Urology Aberdeen Royal Infirmary Aberdeen UK
Department of Urology and Urologic Oncology Hannover Medical School Hannover Germany
Department of Urology Cabueñes Hospital Gijón Spain
Department of Urology Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel
Department of Urology Coimbra University Hospital Coimbra Portugal
Department of Urology Elbe Kliniken Stade Stade Germany
Department of Urology Ludwig Maximilians University Munich Germany
Department of Urology Royal Free Hospital Pond Street London UK
Department of Urology Sunderby Hospital Sunderby Sweden
Department of Urology University Hospital Plzeň Plzeň Czech Republic
Department of Urology University Hospital Schleswig Holstein Lübeck Germany
Department of Urology University of Rennes Rennes France
Division of Urology Maggiore della Carità Hospital University of Eastern Piedmont Novara Italy
Faculty of Medicine in Plzeň Charles University Plzeň Czech Republic
Patient Advocate International Kidney Cancer Coalition Duivendrecht The Netherlands
Specialist Centre for Kidney Cancer Royal Free London NHS Foundation Trust London UK
The Royal Free NHS Trust and Barts Cancer Institute Queen Mary University of London London UK
UCL Division of Surgery and Interventional Science London UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028858
- 003
- CZ-PrNML
- 005
- 20210114155231.0
- 007
- ta
- 008
- 210105s2019 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2019.05.022 $2 doi
- 035 __
- $a (PubMed)31151678
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Albiges, Laurence $u Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
- 245 10
- $a Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma / $c L. Albiges, T. Powles, M. Staehler, K. Bensalah, RH. Giles, M. Hora, MA. Kuczyk, TB. Lam, B. Ljungberg, L. Marconi, AS. Merseburger, A. Volpe, Y. Abu-Ghanem, S. Dabestani, S. Fernández-Pello, F. Hofmann, T. Kuusk, R. Tahbaz, A. Bex,
- 520 9_
- $a Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
- 650 _2
- $a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
- 650 _2
- $a axitinib $x aplikace a dávkování $7 D000077784
- 650 _2
- $a bevacizumab $x aplikace a dávkování $7 D000068258
- 650 _2
- $a karcinom z renálních buněk $x farmakoterapie $x sekundární $7 D002292
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ipilimumab $x aplikace a dávkování $7 D000074324
- 650 _2
- $a nádory ledvin $x farmakoterapie $x patologie $7 D007680
- 650 _2
- $a nivolumab $x aplikace a dávkování $7 D000077594
- 650 _2
- $a sunitinib $x terapeutické užití $7 D000077210
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Powles, Tom $u The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
- 700 1_
- $a Staehler, Michael $u Department of Urology, Ludwig-Maximilians University, Munich, Germany.
- 700 1_
- $a Bensalah, Karim $u Department of Urology, University of Rennes, Rennes, France.
- 700 1_
- $a Giles, Rachel H $u Patient Advocate, International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands; Department of Nephrology and Hypertension, Regenerative Medicine Center, University Medical Centre Utrecht, Utrecht, The Netherlands.
- 700 1_
- $a Hora, Milan $u Department of Urology, University Hospital Plzeň, Plzeň, Czech Republic; Faculty of Medicine in Plzeň, Charles University, Plzeň, Czech Republic.
- 700 1_
- $a Kuczyk, Markus A $u Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
- 700 1_
- $a Lam, Thomas B $u Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
- 700 1_
- $a Ljungberg, Börje $u Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
- 700 1_
- $a Marconi, Lorenzo $u Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
- 700 1_
- $a Merseburger, Axel S $u Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
- 700 1_
- $a Volpe, Alessandro $u Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
- 700 1_
- $a Abu-Ghanem, Yasmin $u Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
- 700 1_
- $a Dabestani, Saeed $u Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Malmö, Sweden.
- 700 1_
- $a Fernández-Pello, Sergio $u Department of Urology, Cabueñes Hospital, Gijón, Spain.
- 700 1_
- $a Hofmann, Fabian $u Department of Urology, Sunderby Hospital, Sunderby, Sweden.
- 700 1_
- $a Kuusk, Teele $u Department of Urology, Royal Free Hospital, Pond Street, London, UK.
- 700 1_
- $a Tahbaz, Rana $u Department of Urology, Elbe Kliniken Stade, Stade, Germany.
- 700 1_
- $a Bex, Axel $u Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK. Electronic address: a.bex@nki.nl.
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 76, č. 2 (2019), s. 151-156
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31151678 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114155229 $b ABA008
- 999 __
- $a ok $b bmc $g 1609193 $s 1120038
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 76 $c 2 $d 151-156 $e - $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20210105
